Effect of styrene maleic anhydride (SMA) on viability and integrity of isolated rat oocytes in vitro

Contraception

Volumn 66, Issue 6, 2002, Pages 469-472

  Chaube, S K ^a   Misro, M M ^a  

^a NATIONAL INSTITUTE OF HEALTH AND FAMILY WELFARE   (India)

Author keywords

Incubation; Medium 199; Oocyte; Polymer (SMA); Viability

Indexed keywords

STYRENE MALEIC ANHYDRIDE COPOLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ISOLATION; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOPLASM; DILUTION; DRUG EFFECT; FEMALE; IN VITRO STUDY; NONHUMAN; OOCYTE; PH; PRECIPITATION; RAT; ZONA PELLUCIDA;

ANIMALS; CELL DEATH; CELLS, CULTURED; CULTURE MEDIA; CYTOPLASM; FEMALE; HYDROGEN-ION CONCENTRATION; MALEATES; OOCYTES; OSMOLAR CONCENTRATION; POLYMERS; POLYSTYRENES; PRECIPITATION; RATS; SOLUTIONS; SPERMATOCIDAL AGENTS;

EID: 0242286059     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(02)00419-5     Document Type: Article

References (11)

1. Neelima, Mehrotra P.K., Bhaduri A.P., Kamboj V.P. Pregnancy interceptive activity of triazoles, oxadiazoles and thiadiazoles. Indian J Med Res. 86:1987;256-259.
2. Shukla R., Mehrotra P.K., Dwivedi A., Kamboj V.P. Pregnane derivatives pregnancy interceptive agents efficacy determination on growing trophoblast (in vitro) and in pregnant hamsters (in vivo) . Contraception. 45:1992;605-612.
3. Mehrotra P.K., Kitchlu S., Batra S., Srivastava S., Bhaduri A.P. Search for new chemical entities as mensus inducing agents. Contraception. 64:2001;187-191.
4. Naz R.K., Leslie M.H., Zhu X. Inhibition of murine sperm-oolemma binding by antibodies to an oocyte membrene (OM) antigen implication in contraceptive vaccine development . Am J Reprod Immunol. 45:2001;52-61.
5. Barber M.R., Lee S.M., Steffens W.L., et al. Immunolocalization of zona pellucida antigens in the ovarian follicle of dogs, cats, horses and elephants. Theriogenology. 55:2001;1705-1717.
6. Guha S.K., Singh G., Anand S., et al. Phase I clinical trial of an injectable contraceptive for the male. Contraception. 48:1993;367-375.
7. Guha S.K., Singh G., Ansari S., et al. Phase II clinical trial of a vas deferens injectable contraceptive for the male. Contraception. 56:1997;245-250.
8. Misro M.M., Guha S.K., Sigh H., et al. Injectable non-occlusive chemical contraception in the male. Contraception. 20:1979;467-473.
9. Guha S.K., Ansari S., Anand S., et al. Contraception in male monkey by intra-vas deferens injection of pH-lowering polymer. Contraception. 32:1985;109-118.
10. Guha SK. Contraceptive for use by a male. US Patent 5488075, 1996.
11. Sharma U., Chaudhury K., Jagannathan N.R., Guha S.K. A proton NMR study on the effect of a new intravasal injectable male contraceptive RISUG on seminal plasma metabolites. Reproduction. 122:2001;431-436.